CRISPR Therapeutics' (CRSP) "Buy" Rating Reaffirmed at HC Wainwright

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $65.00 target price on the stock. HC Wainwright's price target points to a potential upside of 68.05% from the stock's current price.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus lowered their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a report on Friday. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research report on Friday, February 14th. The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Truist Financial increased their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Stock Down 0.2%

Shares of CRISPR Therapeutics stock opened at $38.68 on Tuesday. The stock has a market cap of $3.34 billion, a P/E ratio of -8.85 and a beta of 1.88. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $67.88. The business's 50 day moving average is $37.40 and its 200-day moving average is $42.24.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.43) EPS. On average, sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its holdings in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock worth $345,929,000 after buying an additional 1,192,336 shares in the last quarter. Capital International Investors lifted its position in shares of CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after acquiring an additional 816,789 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock worth $66,452,000 after purchasing an additional 1,262,560 shares during the period. Finally, Vanguard Group Inc. increased its stake in CRISPR Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after purchasing an additional 33,711 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.